Event Participants
Executives
3 Deval Shah, Sanjay Majmudar, Swapnil Shah
Analysts
12 Aanchal Maheshwari, Aniket Madhwani, Divyam Ketan Doshi, Gaurav Shukla, Harshit Pandey, Pranav Chawla, Parth Soda, Rushikesh Vrajesh Shah, Siddharth Nigam, Smith Doshi, Umesh Laddha, Utkarsh Somaiya
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from operations | ₹180 crores | +36% YoY; driven by robust regulated market growth. |
| Regulated markets revenue | +42% YoY | Strongest growth engine; supported by portfolio expansion and differentiated sales channels. |
| Emerging markets revenue | +30% YoY | Steady momentum; business turned cash-flow positive. |
| India branded generics revenue | ₹8 crores | ~2% YoY decline; strategy shifted to profitability over sales build-up. |
| EBITDA | ₹54 crores | +87% YoY; strong operating leverage. |
| EBITDA margin | ~30% | +810 bps YoY; gross margin improved ~1% QoQ. |
| PAT | ₹31 crores | +56% YoY; prior quarter had ~₹14-15 crores forex fluctuation, absent this quarter. |
| Emerging markets EBITDA margin | 14% in Q1 | Down from 20% in Q4 FY26 due to H1 seasonality; full-year guided at 18-20%. |
| Operating cash flow – emerging markets | ₹18 crores | Quarterly cash generation, confirming cash-flow positive status. |
| Approved ANDAs | 58 | Nearly doubled from 30 in June 2025; 23 commercialized. |
| ANDA pipeline | 39 molecules, 110+ strengths | Under various development stages; excludes approved but unlaunched products. |
| Apnar facility production | ~30 million units (Q1) | Six products commercialized; utilization ~80-90%, including validation and launch batches. |
| Capex guidance FY27 | ₹100-120 crores | Oral solids capacity expansion and injectable pilot plant. |
Geographic & Segment Commentary
Regulated Markets: Revenue grew 42% YoY, driven by an expanded ANDA portfolio (58 approved, 35 mapped for commercialization over next 18-20 months) and a four-pronged go-to-market model—Zuraya (own label), Amerisource (government business), B2B licensing, and CDMO/CMO. Apnar facility is ramping with six products commercialized, and Zuraya/Amerisource operations begin September-October 2026.
Emerging Markets: Revenue grew 30% YoY; EBITDA margins improved to mid-teens and the business is cash-flow positive with ₹18 crores operating cash generated in Q1. Q1 margin came in at 14% (vs 20% in Q4 FY26) due to H1 seasonality, but management is confident of 18-20% full-year EBITDA margins. PIC/S approval for Chhatral facility expected in Q2-Q3, unlocking markets such as Vietnam, South Africa, and Mexico.
India Branded Generics: Revenue was ₹8 crores in Q1, roughly flat YoY, reflecting a deliberate pivot toward profitability (35-40% EBITDA target) rather than aggressive sales growth. Management expects ₹50-60 crores revenue for FY27.
Company-Specific & Strategic Commentary
ANDA Portfolio Expansion: Approved ANDAs nearly doubled from 30 (June 2025) to 58 (June 2026); 23 are commercialized. Another 39 molecules / 110+ strengths are in development, providing multi-year growth visibility.
Apnar Facility Ramp-Up: The Baroda-based US FDA-approved plant produced ~30 million units in Q1; six products commercialized and 18 products mapped. Third and fourth production lines are being added to support capacity expansion.
US Commercial Infrastructure: Zuraya (own-label products) and Amerisource (government-generic sales) subsidiaries are slated to commence operations in September-October 2026, structurally advancing the US business.
IPO Proceeds Reallocation: Management scaled down the sterile injectables project and reallocated proceeds to oral solid capacity expansion; a smaller injectable pilot plant is being pursued, subject to shareholder approval.
PIC/S Certification: Chhatral facility inspection completed; approval expected Q2-Q3, expanding access to mid-tier regulated markets like Vietnam, South Africa, and Mexico, with peak sales estimated at $15-20 million.
Emerging Market Profitability: The segment is now cash-flow positive, with EBITDA margins guided at 18-20% for FY27 despite Q1 seasonality.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 revenue growth | 30-40% | Based on current business outlook and visible commercial launches over coming quarters. |
| FY27 PAT growth | 50-60% | Similar growth trajectory expected thereafter. |
| Long-term revenue | ₹2,500-3,000 crores in 3-4 years | Based on existing approved/pipeline products; excludes NDA opportunities. |
| Emerging markets EBITDA margin | 18-20% for FY27 | Q1 at 14% due to H1 seasonality; H2 historically strong. |
| India branded generics revenue | ₹50-60 crores for FY27 | Focus on profitability (35-40% EBITDA) over absolute sales. |
| Capex | ₹100-120 crores FY27; ₹60-70 crores FY28 run-rate | Oral solids capacity, Apnar lines 3-4, injectable pilot. |
| PIC/S approval | Chhatral facility by Q2-Q3 | Unlocks Vietnam, South Africa, Mexico, and other markets. |
| Zuraya/Amerisource operational | September-October 2026 | US-specific sales and distribution subsidiaries. |
Risks & Constraints
| Risk | Context |
|---|---|
| US generic import tariffs | Potential tariffs flagged for 2028; management is awaiting the India-US trade agreement for clarity. Mitigation exists via US manufacturing capability, making the company relatively neutral. |
| ANDA launch execution | 35 approved ANDAs are planned for commercialization over 18-20 months; success depends on FDA approvals, plant capacity, and commercial partnerships. Delays could impact the FY27 growth trajectory. |
| Sterile injectable scale-down | Reallocation of IPO proceeds to oral solids reduces near-term injectable upside; pilot approach may defer meaningful contribution from injectables. |
| H1 seasonality / margin volatility | Q1 emerging market margin (14%) trailed Q4 (20%); full-year guidance of 18-20% relies on a strong H2. Forex fluctuations can distort quarterly comparatives. |
| Regulatory approvals in new markets | PIC/S and 900+ pending MOH registrations are subject to approval timelines; delays would shift revenue contribution from emerging and new markets. |
Q&A Highlights
Emerging Market Margin Trajectory
- Question: Why did emerging market EBITDA margin decline from 20% in Q4 FY26 to 14% in Q1 FY27? (Rushikesh Vrajesh Shah, Alchemy Capital)
- Answer: H1 is seasonally weak; Q1 FY26 was in single digits. Full-year margin guidance remains 18-20%. Gross margin actually improved ~1% QoQ. (Swapnil Shah)
ANDA Portfolio, Gross Margins and Commercial Mapping
- Question: Is the sharp jump in ANDAs due to acquisitions? Where do gross margins settle? (Siddharth Nigam, CWC)
- Answer: Portfolio growth includes acquisitions plus in-house development and CDMO/CMO expansion. Every ANDA is commercially mapped through Zuraya, Amerisource, B2B licensing, or CDMO/CMO. Sequential margin dip was largely due to ₹14-15 crores forex fluctuation in Q4, not operational weakness. (Swapnil Shah; Deval Shah)
Launch Cadence and FY27 Guidance
- Question: Seven products launched this quarter but no visible sequential top-line jump—should we expect QoQ improvement? (Pranav Chawla, JM AMC)
- Answer: Launches this quarter were not yet material to revenue. Management is sticking to FY27 guidance of 30-40% revenue growth; a revision could be discussed after a couple of quarters if needed. (Swapnil Shah)
IPO Proceeds Reallocation / Sterile Injectables
- Question: Update on the sterile injectable project with ~₹100 crores IPO proceeds unutilized. (Parth Soda, Trinetra Asset Managers)
- Answer: The project has been scaled down and proceeds reallocated to oral solid capacity; injectables will proceed as a smaller pilot plant. Change in object is subject to shareholder approval. (Swapnil Shah; Deval Shah)
Apnar Commercialization and US Tariffs
- Question: How many products have been commercialized from Apnar, and what about US API import tariffs? (Aanchal Maheshwari, Niraadhi Investment)
- Answer: Six products commercialized to date; ~30 million units produced in Q1, with 18 products mapped. Tariff risk is mitigated by US manufacturing footprint; management is waiting for the India-US trade agreement for clarity. (Swapnil Shah)
US Subsidiary Ramp-Up and Capex
- Question: When will Zuraya start operations? What is Apnar utilization and capex outlook? (Umesh Laddha, Ambit Capital)
- Answer: Zuraya and Amerisource will be operational from September-October 2026. Apnar is at 80-90% utilization including validation/qualification batches. FY27 capex is ₹100-120 crores; next year's run-rate is ₹60-70 crores. (Swapnil Shah; Deval Shah)
PIC/S-Driven New Markets and NDA Pipeline
- Question: How large is the EU/PIC/S opportunity and are NDA products included in guidance? (Divyam Ketan Doshi, 923 Capital)
- Answer: 100-120 products are expected to be filed in these markets; peak sales estimated at $15-20 million. NDA opportunities exist but are premature; they are not included in the ₹2,500-3,000 crores long-term target. (Swapnil Shah)
FY28 Growth and Long-Term Trajectory
- Question: Can we expect similar PAT growth in FY28? (Utkarsh Somaiya, EcoQuantum Solutions)
- Answer: No specific FY28 number yet; management's aim is ₹2,500-3,000 crores revenue in 3-4 years, sustaining ~30% EBITDA as a minimum. (Swapnil Shah)
Key Takeaway
Senores Pharmaceuticals delivered a strong Q1 FY27, with consolidated revenue of ₹180 crores (+36% YoY), EBITDA of ₹54 crores (+87% YoY, ~30% margin), and PAT of ₹31 crores (+56% YoY), driven by 42% growth in regulated markets and 30% in emerging markets. The company nearly doubled its approved ANDA portfolio to 58 (23 commercialized) and reiterated FY27 guidance of 30-40% revenue growth and 50-60% PAT growth, backed by a ₹2,500-3,000 crore revenue target over 3-4 years. Strategically, management is ramping Apnar (six products commercialized, ~30 million units in Q1), operationalizing Zuraya and Amerisource in H2 FY27, and reallocating IPO proceeds toward oral solid capacity while keeping injectables as a pilot. Emerging markets are cash-flow positive, with full-year EBITDA margins guided at 18-20%. Key watch points include timely execution of 35 planned ANDA launches, potential US generic tariffs in 2028, and H2-weighted seasonality. Management remains confident of sustaining a similar growth trajectory beyond FY27.